Dow and Avidex Agree to Develop Biotargeted Radiopharmaceuticals Based on mTCR Technology
Agreement applies ChelaMed services to enhance Avidex's Monoclonal T Cell Receptors
05-Sep-2003 -
Avidex Limited and The Dow Chemical Company will collaborate to create biotargeted radiopharmaceuticals for cancer treatment by applying Dow's technology to Avidex's monoclonal T cell receptors (mTCRs).
Under the agreement, proprietary chelation technology and other capabilities, provided ...
bladder cancer
diseases
Dow
+6